Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes

Inaba, 2013, Acute lymphoblastic leukaemia, Lancet, 381, 1943, 10.1016/S0140-6736(12)62187-4 Terwilliger, 2017, Acute lymphoblastic leukemia: a comprehensive review and 2017 update, Blood Cancer J, 7, e577, 10.1038/bcj.2017.53 Arber, 2016, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, 127, 2391, 10.1182/blood-2016-03-643544 Ludwig, 1990, [Incidence, clinical markers and prognostic significance of immunologic subtypes of acute lymphoblastic leukemia (ALL) in children: experiences of the ALL-BFM 83 and 86 studies], Klin Pediatr, 202, 243, 10.1055/s-2007-1025528 Möricke, 2010, Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000, Leukemia, 24, 265, 10.1038/leu.2009.257 Parker, 2010, Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial, Lancet, 376, 2009, 10.1016/S0140-6736(10)62002-8 Tallen, 2010, Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90, J Clin Oncol, 28, 2339, 10.1200/JCO.2009.25.1983 Pui, 2008, Acute lymphoblastic leukaemia, Lancet, 371, 1030, 10.1016/S0140-6736(08)60457-2 Mullighan, 2011, CREBBP mutations in relapsed acute lymphoblastic leukaemia, Nature, 471, 235, 10.1038/nature09727 Meyer, 2013, Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia, Nat Genet, 45, 290, 10.1038/ng.2558 Oskarsson, 2018, Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia, Pediatr Blood Cancer, 65, e26909, 10.1002/pbc.26909 Mustafa, 2019, FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies, J Oncol Pharm Pract, 25, 1831, 10.1177/1078155218817816 Crotta, 2018, Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia, Curr Med Res Opin, 34, 435, 10.1080/03007995.2017.1384373 Hunger, 2015, Acute lymphoblastic leukemia in children, N Engl J Med, 373, 1541, 10.1056/NEJMra1400972 Tomuleasa, 2018, Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia, Front Immunol, 9, 239, 10.3389/fimmu.2018.00239 Hartmann, 2017, Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts, EMBO Mol Med, 9, 1183, 10.15252/emmm.201607485 Kueberuwa, 2018, CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity, Mol Ther Oncolytics, 8, 41, 10.1016/j.omto.2017.12.003 Chmielewski, 2015, TRUCKs: the fourth generation of CARs, Expert Opin Biol Ther, 15, 1145, 10.1517/14712598.2015.1046430 Anagnostou, 2019, Directed chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia: a systematic review and meta-analysis, Biol Blood Marrow Transpl, 25, S169, 10.1016/j.bbmt.2018.12.308 Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, J Clin Epidemiol, 62, e1, 10.1016/j.jclinepi.2009.06.006 Balduzzi, 2019, How to perform a meta-analysis with R: a practical tutorial, Evid Based Ment Health, 22, 153, 10.1136/ebmental-2019-300117 Curran, 2014, Chimeric antigen receptor (CAR) T cells targeting the CD19 antigen for the treatment of pediatric relapsed B cell ALL, Blood, 134, 2361, 10.1182/blood.2019001641 Gardner, 2017, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208 Ghorashian, 2019, Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR, Nat Med, 25, 1408, 10.1038/s41591-019-0549-5 Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866 Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3 Ma, 2018, Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor modified T cells in a phase i study targeting pediatrics with acute lymphoblastic leukemia, Blood, 132, 601, 10.1182/blood-2018-99-114346 Lee, 2017, ZUMA-4 preliminary results: phase 1 study of KTE-C19 chimeric antigen receptor T cell therapy in pediatric and adolescent patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL), Ann Oncol, 28, v360, 10.1093/annonc/mdx373.014 Leahy, 2019, Cytogenetic characteristics and outcomes of patients receiving CTL019 car T cell therapy, Blood, 134, 1464, 10.1182/blood-2019-130060 Talleur, 2019, Autologous CD19-CAR T-cells for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients: an initial report from an institutional phase I/II study, Clin Lymphoma Myeloma Leuk, 19, S265, 10.1016/j.clml.2019.07.186 Hiramatsu, 2020, Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia, Int J Hematol, 111, 303, 10.1007/s12185-019-02771-2 Ceppi, 2018, Minimal change in CAR T cell manufacturing can impact in expansion and side effect of the CAR T cell therapy, Blood, 132, 4012, 10.1182/blood-2018-99-110164 Del Bufalo, 2019, Blood, 134, 1341, 10.1182/blood-2019-129821 Dourthe, 2019, Safety and efficacy of tisagenlecleucel (CTL019) in B-cell acute lymphoblastic leukemia in children, adolescents and young adults: the French experience, Blood, 134, 3876, 10.1182/blood-2019-131123 Zuo, 2019, [Chimeric antigen receptors T cells for treatment of 48 relapsed or refractory acute lymphoblastic leukemia children: long term follow-up outcomes], Zhonghua Xue Ye Xue Za Zhi, 40, 270 Shen, 2020, Chimeric antigen receptor T cell therapy can be administered safely under the real-time monitoring of Th1/Th2 cytokine pattern using the cytometric bead array technology for relapsed and refractory acute lymphoblastic leukemia in children, Pediatr Hematol Oncol, 37, 288, 10.1080/08880018.2019.1704325 von Stackelberg, 2016, Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia, J Clin Oncol, 34, 4381, 10.1200/JCO.2016.67.3301 Yaniv, 2018, Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study, Biol Blood Marrow Transpl, 24, 1629, 10.1016/j.bbmt.2018.03.002 Jacoby, 2018, Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia, Am J Hematol, 93, 1485, 10.1002/ajh.25274 Yang, 2019, Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation, Hematol Oncol, 37, 655, 10.1002/hon.2682 Gofshteyn, 2018, Neurotoxicity after CTL019 in a pediatric and young adult cohort, Ann Neurol, 84, 537, 10.1002/ana.25315 Singh, 2017, Monocyte lineage–derived IL-6 does not affect chimeric antigen receptor T-cell function, Cytotherapy, 19, 867, 10.1016/j.jcyt.2017.04.001 Agostini, 2016, Prophylactic immunoglobulin therapy in secondary immune deficiency—an expert opinion, Expert Rev Clin Immunol, 12, 921, 10.1080/1744666X.2016.1208085 Xu, 2019, Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies, Front Immunol, 10, 2664, 10.3389/fimmu.2019.02664